Members of the trefoil family are characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfide bonds. They are stable secretory proteins expressed in gastrointestinal mucosa. Their functions are diverse, including protection of the mucosa, thickening of the mucus, and increasing epithelial healing rates. This gene is a marker of columnar epithelium and is expressed in a variety of tissues including goblet cells of the intestines and colon. This gene and two other related trefoil family member genes are found in a cluster on chromosome 21.[7]
All three human trefoil factors are lectins that interact specifically with the disaccharideGlcNAc-α-1,4-Gal.[8] This disaccharide is an unusual glycotope that is only known to exist on the large, heavily glycosylated, mucins in the mucosa. By cross-linking mucins through the bivalent binding of this glycotope, the trefoil factors are then able to reversible modulate the thickness and viscosity of the mucus.[8]
Trefoil factors (TFF) are secretory products of mucin producing cells. They play a key role in the maintenance of the surface integrity of oral mucosa and enhance healing of the gastrointestinal mucosa by a process called restitution. TFF comprises the gastric peptides (TFF1), spasmolytic peptide (TFF2), and the intestinal trefoil factor (TFF3, this protein). They have an important and necessary role in epithelial restitution within the gastrointestinal tract. Significant amounts of TFF are present in human milk. Evidence has been presented that TFF3 isolated from milk strongly correlates with downregulation of IL-6 and IL-8 in human intestinal epithelial cells. On the other hand, TFF3 activated the epithelial cells in culture to produce beta-defensin 2 (hBD2) and beta defensins 4 (hBD4). These findings suggest that TFF can activate intestinal epithelial cells and could actively participate in the immune system of breastfed babies by inducing the production of peptides related to innate defence, such as defensins.[9]
Two main mechanisms have been described for the activation of PAR-2: (A) by specific cleavage that unmask the receptor-activating peptide sequence present in the extracellular N-terminal domain of each PAR, leading to cell signaling via interaction of the exposed tethered ligand with the body of the receptor itself; and (B) by synthetic peptides, such as SLIGKV, that bind to the receptor, mimicking the actions of agonist proteases.[10] During lactation, TFF3 secreted in human milk may activate intestinal epithelial cells through PAR-2 receptors, which in turn induces hBD2 and hBD4 expression and cytokine regulation.[10]
Using TFF3 as a marker of columnar epithelium, a process using an ingestible oesophageal sampling device (Cytosponge) coupled with immunocytochemistry for trefoil factor 3 to improve the accuracy and acceptability of the detection/screening of Barrett's oesophagus has been developed.[11]
However the clinical utility of such a test may be limited by frequent staining of TFF3 in gastric cardia and subsequent risk of false positives.[12]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK (May 1995). "Characterization of human and rat intestinal trefoil factor produced in yeast". Biochemistry. 34 (14): 4757–64. doi:10.1021/bi00014a033. PMID7718582.
^Peitz U, Kouznetsova I, Wex T, Gebert I, Vieth M, Roessner A, Hoffmann W, Malfertheiner P (2004). "TFF3 expression at the esophagogastric junction is increased in gastro-esophageal reflux disease (GERD)". Peptides. 25 (5): 771–7. doi:10.1016/j.peptides.2004.01.018. PMID15177871. S2CID23122603.
Hoffmann W, Jagla W, Wiede A (2001). "Molecular medicine of TFF-peptides: from gut to brain". Histol. Histopathol. 16 (1): 319–34. PMID11193208.
Hoffmann W, Jagla W (2002). "Cell type specific expression of secretory TFF peptides: colocalization with mucins and synthesis in the brain". Int. Rev. Cytol. International Review of Cytology. 213: 147–81. doi:10.1016/S0074-7696(02)13014-2. ISBN978-0-12-364617-0. PMID11837892.
Langer G, Jagla W, Behrens-Baumann W, et al. (2003). "Ocular TFF-peptides: new mucus-associated secretory products of conjunctival goblet cells". Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. Adv. Exp. Med. Biol. Vol. 506. pp. 313–6. doi:10.1007/978-1-4615-0717-8_44. ISBN978-1-4613-5208-2. PMID12613926.
Seib T, Dooley S, Welter C (1995). "Characterization of the genomic structure and the promoter region of the human intestinal trefoil factor". Biochem. Biophys. Res. Commun. 214 (1): 195–9. doi:10.1006/bbrc.1995.2274. PMID7669039.
Schmitt H, Wundrack I, Beck S, et al. (1996). "A third P-domain peptide gene (TFF3), human intestinal trefoil factor, maps to 21q22.3". Cytogenet. Cell Genet. 72 (4): 299–302. doi:10.1159/000134208. PMID8641134.
Chinery R, Williamson J, Poulsom R (1997). "The gene encoding human intestinal trefoil factor (TFF3) is located on chromosome 21q22.3 clustered with other members of the trefoil peptide family". Genomics. 32 (2): 281–4. doi:10.1006/geno.1996.0117. PMID8833157.
Seib T, Blin N, Hilgert K, et al. (1997). "The three human trefoil genes TFF1, TFF2, and TFF3 are located within a region of 55 kb on chromosome 21q22.3". Genomics. 40 (1): 200–2. doi:10.1006/geno.1996.4511. PMID9070946.
Berry A, Scott HS, Kudoh J, et al. (2001). "Refined localization of autosomal recessive nonsyndromic deafness DFNB10 locus using 34 novel microsatellite markers, genomic structure, and exclusion of six known genes in the region". Genomics. 68 (1): 22–9. doi:10.1006/geno.2000.6253. PMID10950923.
Wiede A, Hinz M, Canzler E, et al. (2001). "Synthesis and localization of the mucin-associated TFF-peptides in the human uterus". Cell Tissue Res. 303 (1): 109–15. doi:10.1007/s004410000297. PMID11235998. S2CID35516062.
Yamachika T, Werther JL, Bodian C, et al. (2002). "Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma". Clin. Cancer Res. 8 (5): 1092–9. PMID12006524.
